基本信息
浏览量:1
职业迁徙
个人简介
His research focuses on the design and discovery of chemical tools to study cellular processes relevant to human disease. Areas of interest include the structure-based design of covalent inhibitors and chemoproteomic probes, as well as mechanistic studies of biologically active natural products. Work in Jack’s lab has led to the development of rilzabrutinib, a reversible covalent BTK inhibitor in clinical trials for immune thrombocytopenia. He is a cofounder of Principia BioPharma, Global Blood Therapeutics, Kezar Life Sciences and Cedilla Therapeutics, and a scientific advisor to Entos.
研究兴趣
论文共 193 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nature chemical biologypp.1-8, (2024)
Nicole A. Wenzell,Brian B. Tuch,Dustin L. McMinn, Matthew J. Lyons, Christopher J. Kirk,Jack Taunton
Nature Chemical Biologypp.1-10, (2024)
Protein science : a publication of the Protein Societyno. 8 (2023): e4712-e4712
Nature chemistryno. 11 (2023): 1616-1625
Natureno. 7959 (2023): 200-207
Keely Oltion,Jordan D. Carelli,Tangpo Yang, Stephanie K. See,Hao-Yuan Wang,Martin Kampmann,Jack Taunton
biorxiv(2022)
bioRxivno. 12 (2022): 1443-1450
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn